MANAGEMENT AND OUTCOME OF RADIOTHERAPY FOR BREAST CANCER: A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/zvmth272Keywords:
Breast cancer, irradiation, therapy, WBIAbstract
Background: A key component of breast cancer treatment is breast irradiation therapy, which provides the best control and precision. Fractionated whole-breast irradiation, or WBI, is the recommended approach for best outcomes. The goal of this study is to conduct a thorough evaluation of the literature from the previous ten years about the administration and results of radiation therapy for breast cancer.
Methods: Using the PRISMA 2020 principles, this systematic review concentrated on full-text English literature that was published between 2014 and 2024. Submissions without a DOI, editorials, and review papers from the same publication were not taken into consideration. Online resources like ScienceDirect, SagePub, and PubMed were used to compile the literature.
Result: More than 100,000 papers were first obtained by our research team from reliable sources like Science Direct, PubMed, and SagePub. Only six publications were found to be directly relevant to our ongoing systematic review using a rigorous three-level screening approach. These articles were then chosen for additional examination by in-depth full-text reading.
Conclusion: An essential component of breast cancer treatment is adjuvant radiation, which eliminates any remaining cancer in the surgery room and surrounding satellites. Shorter courses are preferred for patients with localized breast cancer to preserve early-stage illness and manage tumors.
References
Burkon, P., Selingerova, I., Slavik, M., Holanek, M., Vrzal, M., Coufal, O., Polachova, K., Muller, P., Slampa, P., & Kazda, T. (2024). Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study. Radiation Oncology, 19(1), 1–12. https://doi.org/10.1186/s13014-024-02412-x
Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., Dobbs, H. J., Hopwood, P., i.Lawton, P. A., Magee, B. J., Mills, J., Simmons, S., Sydenham, M. A., Venables, K., Bliss, J. M., & Yarnold, J. R. (2013). The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. The Lancet Oncology, 14(11), 1086–1094. https://doi.org/10.1016/S1470-2045(13)703863
Vicini, F. A., Cecchini, R. S., White, J. R., Arthur, D. W., Julian, T. B., Rabinovitch, R. A., Kuske, R. R., Ganz, P. A., Parda, D. S., Scheier, M. F., Winter, K. A., Paik, S., Kuerer, H. M., Vallow, L. A., Pierce, L. J., Mamounas, i.E. P., McCormick, B., Costantino, J. P., Bear, H. D., … Wolmark, N. (2019). Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. The Lancet, 394(10215), 2155–2164. https://doi.org/10.1016/S0140-6736(19)32514-0
Flanagan, M. R., Zabor, E. C., Romanoff, A., Fuzesi, S., Stempel, M., Mehrara, B. J., Morrow, M., Andrea, L., & i.Gemignani, M. L. (2020). HHS Public Access. 26(10), 3133–3140. https://doi.org/10.1245/s10434-01907548-9.A
Coles, C. E., Haviland, J. S., Kirby, A. M., Griffin, C. L., Sydenham, M. A., Titley, J. C., Bhattacharya, I., Brunt, A. i.M., Chan, H. Y. C., Donovan, E. M., Eaton, D. J., Emson, M., Hopwood, P., Jefford, M. L., Lightowlers, ii.S. V., Sawyer, E. J., Syndikus, I., Tsang, Y. M., Twyman, N. I., … Bliss, J. M. (2023). Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. The Lancet, 401(10394), 2124–2137. https://doi.org/10.1016/S0140-6736(23)00619-0
Yadav, B. S., Sharma, S., Singh, G., & Dahiya, D. (2020). Comparison of two radiation boost schedules in postlumpectomy patients with breast cancer. Journal of Cancer Research and Therapeutics, 16(7), 1344– 1349. https://doi.org/10.4103/jcrt.JCRT
Yadav, B. S., Dahiya, D., Kannan, P., Goyal, S., Laroiya, I., Irrinki, S., Singh, N. R., & Sharma, R. (2024). i.HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial. Trials, 25(1), 1–8. https://doi.org/10.1186/s13063-023-07851-7
Brunt, A. M., Haviland, J. S., Wheatley, D. A., & Sydenham, M. A. (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. 395, 1613–1626.
Strnad, V., Major, T., Polgar, C., Lotter, M., Guinot, J. L., Gutierrez-Miguelez, C., Galalae, R., Van Limbergen, E., Guix, B., Niehoff, P., Lössl, K., & Hannoun-Levi, J. M. (2018). ESTRO-ACROP guideline: Interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost – GECESTRO Breast Cancer Working Group practical recommendations. Radiotherapy and Oncology, 128(3), 411–420. https://doi.org/10.1016/j.radonc.2018.04.009
Strnad, V., Krug, D., Sedlmayer, F., Piroth, M. D., Budach, W., Baumann, R., Feyer, P., Duma, M. N., Haase, W., Harms, W., Hehr, T., Fietkau, R., Dunst, J., & Sauer, R. (2020). DEGRO practical guideline for partialbreast irradiation. Strahlentherapie Und Onkologie, 196(9), 749–763. https://doi.org/10.1007/s00066-02001613-z
Bergom, C., Currey, A., Desai, N., Tai, A., & Strauss, J. B. (2018). Deep inspiration breath hold: Techniques and advantages for cardiac sparing during breast cancer irradiation. Frontiers in Oncology, 8(APR), 1–10. i.https://doi.org/10.3389/fonc.2018.00087
Laughlin, B. S., Corbin, K. S., Toesca, D. A. S., Thorpe, C. S., Golafshar, M. A., Pockaj, B., Cronin, P., McGee, L. A., Halyard, M. Y., Mutter, R. W., Keole, S. R., Park, S. S., Shumway, D. A., Vern-Gross, T. Z., Vallow, L., Wong, W. W., DeWees, T. A., & Vargas, C. E. (2024). Physician- and Patient-Reported Outcomes of the MC1635 Phase 3 Trial of Ultrahypofractionated Versus Moderately Hypofractionated Adjuvant Radiation Therapy After Breast-Conserving Surgery. International Journal of Radiation Oncology Biology i.Physics, 118(4), 1049–1059. https://doi.org/10.1016/j.ijrobp.2023.10.018
Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., Bhattacharya, I. S., Brunt, A. M., Ciurlionis, L., Chan, C., Donovan, E. M., Emson, M. A., Harnett, A. N., Haviland, J. S., Hopwood, P., i.Jefford, M. L., Kaggwa, R., Sawyer, E. J., Syndikus, I., … Thompson, A. (2017). Partial-breast radiotherapy ii.after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The Lancet, 390(10099), 1048–1060. https://doi.org/10.1016/S0140-6736(17)31145-5
Parekh, A., Fu, W., Hu, C., Shen, C. J., Alcorn, S., Rao, A. D., Asrari, F., Camp, M. S., & Wright, J. L. (2018). Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database. Breast Cancer Research and Treatment, 172(1), 201–208. https://doi.org/10.1007/s10549-018-4881-0
Bonin, K., McGuffin, M., Presutti, R., Harth, T., Mesci, A., Feldman-Stewart, D., Chow, E., Di Prospero, L., Vesprini, D., Rakovitch, E., Lee, J., Paszat, L., Doherty, M., Soliman, H., Ackerman, I., Cao, X., Kiss, A., & i.Szumacher, E. (2018). Breast Cancer Patients’ Preferences for Adjuvant Radiotherapy Post Lumpectomy: Whole Breast Irradiation vs. Partial Breast Irradiation—Single Institutional Study. Journal of Cancer Education, 33(1), 37–43. https://doi.org/10.1007/s13187-016-1016-3
Lewis, P., Brunt, A. M., Coles, C., Griffin, S., Locke, I., & Roques, T. (2021). Moving Forward Fast with FASTForward. Clinical Oncology, 33(7), 427–429. https://doi.org/10.1016/j.clon.2021.04.007
van Maaren, M. C., de Munck, L., de Bock, G. H., Jobsen, J. J., van Dalen, T., Linn, S. C., Poortmans, P., Strobbe, L. i.J. A., & Siesling, S. (2016). 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. The Lancet Oncology, ii.17(8), 1158–1170. https://doi.org/10.1016/S1470-2045(16)30067-5
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
